SpinalCyte Rebrands to FibroGenesis

SpinalCyte introduced a new company name, FibroGenesis, reflecting its intellectual property portfolio that includes a treatment for degenerative disc disease (DDD) and other chronic diseases.

The company's CybroCell™ is reportedly the first off-the-shelf allogenic human dermal fibroblast product for the treatment of DDD. In...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us